ARICEPT ODT
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ARICEPT ODT by Eisai is alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Approved for dementia of the alzheimer’s type. First approved in 2004.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARICEPT ODT is an orally disintegrating tablet formulation of donepezil hydrochloride, a cholinesterase inhibitor approved for dementia of the Alzheimer's type. The drug enhances cholinergic neurotransmission by reversibly inhibiting acetylcholinesterase, thereby increasing acetylcholine concentration in the brain. The ODT formulation improves patient convenience and compliance, particularly for patients with dysphagia or those requiring simplified medication administration.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling likely team consolidation and shift toward lifecycle management.
Mechanism of Action
Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition…
Indications (1)
Career Relevance
Working on ARICEPT ODT offers exposure to lifecycle management and LOE strategy execution rather than launch or growth dynamics. Career development is best suited for professionals seeking expertise in mature product optimization, generics defense, and cost-of-goods reduction.
Worked on ARICEPT ODT at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.